SSRI Use During Pregnancy and Postpartum Period

Selection of SSRIs in Pregnancy

• Sertraline should be considered first-line therapy due to minimal excretion in breast milk and low infant-to-maternal plasma concentration ratios, as recommended by the American Academy of Pediatrics 1

Considerations for SSRI Use During Pregnancy

• Third-trimester SSRI use may lead to neonatal signs including irritability, jitteriness, tremors, feeding difficulty, sleep disturbance, and respiratory distress, with symptoms typically appearing within hours to days after birth and usually resolving within 1-2 weeks, according to the American Academy of Pediatrics 1, 2, 3
• SSRI treatment should be continued during pregnancy at the lowest effective dose, as withdrawal of medication may have harmful effects on the mother-infant dyad, as stated by the American Academy of Pediatrics 1

Postpartum and Breastfeeding Considerations

• Sertraline is minimally excreted in breast milk, providing the infant with less than 10% of the maternal daily dose, and can be continued during breastfeeding, as recommended by the American Academy of Pediatrics 1

Monitoring and Follow-up

• Clinicians should arrange for early follow-up after initial hospital discharge for infants exposed to SSRIs, and monitor infants for signs of drug toxicity or withdrawal over the first week of life, according to the American Academy of Pediatrics 1, 2
• In severely affected infants with persistent symptoms, a short-term course of chlorpromazine has provided measurable relief, as reported by the American Academy of Pediatrics 1
• Several recent reviews have not identified adverse neurodevelopmental outcomes among infants born to women treated with SSRIs during pregnancy, as stated by the American Academy of Pediatrics 1

Clinical Decision Algorithm

• If SSRI treatment is indicated, consider citalopram as an alternative if sertraline is not tolerated or ineffective, as suggested by the American Academy of Pediatrics 2
• Use the lowest effective dose throughout pregnancy and postpartum, and continue treatment through pregnancy rather than discontinuing, as recommended by the American Academy of Pediatrics 1

Safety of Sertraline During Lactation

Preferred Antidepressants During Lactation

• Paroxetine and sertraline are the most commonly prescribed antidepressants during breastfeeding, with both considered suitable first-line agents, according to the American family physician 4

Best Medication for Postpartum Anxiety/Agitation While Breastfeeding

Introduction to Medication Choices

• The American Academy of Family Physicians recommends sertraline as a first-line therapy for breastfeeding mothers with postpartum anxiety and agitation due to its minimal excretion in breast milk and low infant-to-maternal plasma concentration ratios 5

Practical Prescribing Approach

• The American Journal of Obstetrics and Gynecology suggests starting with low doses of sertraline, 25-50 mg daily, and slowly titrating upward while carefully monitoring the newborn 6
• Bupropion could be considered as an alternative for individuals requiring treatment for co-occurring depression, given available safety data in the perinatal period, although it is not as efficacious as SSRIs for anxiety disorders 7, 6, 5

Alternative Considerations

• The American Journal of Obstetrics and Gynecology notes that bupropion has very limited breastfeeding data, with only 21 cases, and two case reports of seizures in breastfed infants, though causality is uncertain 6
• Generally, no adverse events have been reported in most cases of bupropion use during breastfeeding 6

Key Principles

• The American Academy of Family Physicians advises women already taking sertraline to breastfeed and continue the medication rather than discontinue either, as the benefits of breastfeeding for both mother and infant are well-documented, and untreated maternal anxiety/depression poses significant risks to the mother-infant dyad 5

Sertraline Use in Pregnancy

Risks and Considerations

• Late pregnancy SSRI exposure, such as with sertraline, has a possible association with Persistent Pulmonary Hypertension of the Newborn (PPHN), with the number needed to harm being 286-351, according to the American Academy of Family Physicians 8
• No increased risk of cardiac malformations has been demonstrated with first-trimester sertraline use in large population-based studies, as reported by the American family physician 8
• Untreated depression during pregnancy carries significant risks, including premature birth, decreased breastfeeding initiation, and harm to the mother-infant relationship, as noted by the American family physician 8
• The American family physician recommends avoiding paroxetine specifically, which has FDA pregnancy category D classification due to cardiac malformation concerns 8
• Sertraline should be continued during breastfeeding as it transfers in very low concentrations into breast milk, and is one of the two most commonly prescribed antidepressants during lactation, according to the American family physician 8
• Do not avoid treatment altogether due to fear of medication risks, as untreated maternal depression carries substantial documented risks to both mother and infant, as advised by the American family physician 8

Management of Antidepressants in Pregnancy

Discontinuation and Switching Strategies

• The American Psychiatric Association and American College of Obstetricians and Gynecologists recommend that women with severe depression or history of relapse when discontinuing treatment should continue antidepressant use during pregnancy—but this should be with a safer agent like sertraline, not paroxetine 9, 10
• Women who discontinue antidepressants during pregnancy show significantly increased relapse risk of major depression, highlighting the importance of psychiatric consultation before discontinuing treatment 11

Medication Switching and Monitoring

• Transition directly from paroxetine to sertraline without a washout period in most cases to prevent depressive relapse, and monitor the patient for withdrawal symptoms during the transition and for adequate depression control after the switch 9

SSRI Safety in Pregnancy and Neurodevelopmental Outcomes

Neurodevelopmental Effects

• Converging evidence from multiple study designs suggests that observed associations between prenatal antidepressant exposure and neurodevelopmental problems, including autism spectrum disorder and ADHD, are largely due to confounding factors rather than causal medication effects, as reported by the Journal of Child Psychology and Psychiatry and Allied Disciplines 12

Sertraline Use in Pregnancy

Neurodevelopmental Outcomes

• Converging evidence from multiple study designs suggests that observed associations between prenatal antidepressant exposure and autism spectrum disorder or ADHD are largely due to confounding factors, such as maternal psychiatric illness, rather than causal medication effects, according to the American Academy of Pediatrics 13

Clinical Decision Algorithm

• The American College of Obstetricians and Gynecologists recommends choosing sertraline as first-line therapy if SSRI treatment is indicated during pregnancy, due to its safety profile and low risk of cardiac malformations 13

Fluoxetine Use in Pregnancy: Evidence Summary

Neurodevelopmental Outcomes

• Prenatal exposure to fluoxetine does not appear to cause autism spectrum disorder or ADHD; observed associations are likely due to confounding factors such as maternal psychiatric illness rather than a direct medication effect. This conclusion is drawn from multiple study designs (cohort, case‑control, and meta‑analysis) that collectively reduce the likelihood of a causal relationship. Strength of evidence: moderate to high (converging evidence from diverse designs). 14

Maternal and Infant Monitoring Recommendations

• During pregnancy, clinicians should conduct regular monitoring that includes assessment of fetal growth, maternal blood pressure, and ensuring appropriate maternal weight gain. This protocol aims to detect any adverse effects early and to support optimal pregnancy outcomes. Strength of evidence: expert consensus (clinical practice guideline). 15

• After birth, infants of mothers who used fluoxetine should be monitored for adequate weight gain and achievement of developmental milestones throughout the first week of life. Ongoing surveillance helps identify potential drug‑related toxicity or withdrawal symptoms promptly. Strength of evidence: expert consensus (clinical practice guideline). 15